December 7, 2018
Impel NeuroPharma raises a $67,500,000 series D round from KKR.
Impel NeuroPharma raises a $67,500,000 series D round from 5AM Ventures, KKR, Norwest Venture Partners, Vivo Capital and venBio.
December 2, 2016
Impel NeuroPharma raises a $36,000,000 series C round from venBio.
Documentaries, videos and podcasts
May 18, 2021
Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief , an educational initiative which aims to raise awareness of the complexities of migraine, including the underrecognized connection between the brain and gut.
November 9, 2020
/PRNewswire/ -- Impel NeuroPharma, a late-stage biopharmaceutical company, today announced that it has submitted a New Drug Application (NDA) for INP104...
June 10, 2020
Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine - read this article along with other careers information, tips and advice on BioSpace